Form 4: Camp4 Director Buys Shares in Private Placement

Camp4 Therapeutics Director Richard A. Young acquired 15,151 shares of common stock at $1.65 per share in a private placement.

Summary

• Richard A. Young, a Director of Camp4 Therapeutics Corp. (CAMP), acquired 15,151 shares of common stock.
• The transaction occurred on September 11, 2025, at a purchase price of $1.65 per share.
• The shares were acquired in a private placement conducted by Camp4 Therapeutics Corp.
• The private placement was executed pursuant to a Securities Purchase Agreement dated September 9, 2025.
• Participants in the private placement included institutional investors, certain directors, employees, and consultants.
• Following this transaction, Richard A. Young beneficially owns 170,010 shares of Camp4 Therapeutics Corp. common stock.

Sentiment

Score: 7

Explanation: The insider purchase by a director, coupled with the successful execution of a private placement, generally indicates positive sentiment and confidence in the company's future.

Positives

• A Director's purchase of shares in the company demonstrates confidence in the company's future prospects and valuation.
• The private placement indicates successful capital raising for the company, potentially strengthening its financial position.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the private placement suggests the company is securing capital for future operations or strategic initiatives.

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive signal, indicating management's belief in the company's intrinsic value and future performance. Private placements are common methods for biotechnology or early-stage companies like Camp4 Therapeutics to raise capital from a select group of investors.

Related Party Transactions

• The private placement involved participation from certain directors, employees, and consultants, including the reporting person, Richard A. Young.

Stakeholder Impact

• Shareholders may view the director's purchase as a sign of confidence, potentially leading to increased investor interest.
• The capital raised through the private placement provides funding for the company, benefiting all stakeholders by supporting operations and strategic goals.
• Existing shareholders may experience minor dilution from the issuance of new shares in the private placement.

Key Dates

Keywords

Camp4 Therapeutics, CAMP, Insider Buying, Form 4, Private Placement, Director Stock Purchase, Equity Investment